Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton's Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia

Matthew S. Davids, John M. Burke, Jennifer A. Woyach, Mina Shahkarami, Katherine Eakle, Jinnie Ko, Vivek S. Chopra, Weize Huang, Rona Farighi, Richard H. Ko, Jeff P. Sharman, William G. Wierda

Blood (2024) 144 (Supplement 1): 3257.2.

https://doi.org/10.1182/blood-2024-201555

Published: 2024

Journal Articles

Cost-Effectiveness of Emicizumab Vs Efanesoctocog Alfa, Standard Half Life (SHL) and Other Extended Half Life (EHL) FVIII Products for Prophylaxis in People with Severe Hemophilia a without Inhibitors

Randall Curtis, Marquita Decker-Palmer, Michele R Wilson, Cheryl L McDade, Chia-Wei Lin, Chris Wallick, Richard H Ko

Blood (2023) 142 (Supplement 1): 5053.

https://doi.org/10.1182/blood-2023-181062

Published: 2023

Journal Articles

Cost-Effectiveness of Emicizumab for Prophylaxis in People with Severe Hemophilia A without Inhibitors

Marquita Decker-Palmer, Chia-Wei Lin, Michele Wilson, Cheryl McDade, Komal Bawa, Stacey Kowal, Arliene Ravelo, Elaine Yu, Richard H. Ko

Blood (2022) 140 (Supplement 1): 13041–13042.

https://doi.org/10.1182/blood-2022-162276

Published: 2022

Journal Articles

Characterizing Mild and Moderate Hemophilia A Patients in the Real World: A Patient-Centric Approach

Michelle Witkop, Tao Xu, Gillian Hanson, Richard Ofori-Asenso, Richard H. Ko, Emily Cibelli, Martynas Aizenas, Mark W Skinner, Fabian Sanabria, Amy D. Shapiro

Blood (2021) 138 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2021-146543

Published: 2021

Journal Articles

Evaluation of the Safety of Emicizumab Prophylaxis in Persons with Hemophilia A: An Updated Summary of Thrombotic Events and Thrombotic Microangiopathies

Monet Howard, Derrick McKinley, Fabian Sanabria, Richard H. Ko, Francis Nissen

Blood (2021) 138 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2021-146147

Published: 2021

Journal Articles

Improvement in Annualized Bleed Rate in Patients with Hemophilia A Initiating Emicizumab - Physician Reported Outcomes from the Adelphi Hemophilia a Disease Specific Programme™

Rahul Khairnar, Marquita Decker-Palmer, Jennifer Mellor, Keisha Golden, Susanna Libby, Stevie Olsen, Christian Taylor, Craig S Meyer, James Pike, Richard H. Ko

Blood (2021) 138 (Supplement 1): 1961.

https://doi.org/10.1182/blood-2021-147945

Published: 2021

Journal Articles

A Novel Methodology for Building Longitudinal, Patient-Centric Real World Datasets in Hemophilia A

Mark W Skinner, Gillian Hanson, Tao Xu, Richard Ofori-Asenso, Richard H. Ko, Emily Cibelli, Francis Nissen, Michelle Witkop, Fabian Sanabria, Amy D. Shapiro

Blood (2021) 138 (Supplement 1): 594.

https://doi.org/10.1182/blood-2021-146160

Published: 2021

Journal Articles

A Phase IV, Multicenter, Open-Label Study of Emicizumab Prophylaxis in Persons with Hemophilia a with or without FVIII Inhibitors Undergoing Minor Surgical Procedures

Miguel A. Escobar, MD, Amy Dunn, Doris Quon, MD PhD, Ben Trzaskoma, Lucy Lee, Richard H Ko, Shannon L Carpenter, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134906

Published: 2020

Journal Articles

Characterization and Disease Management of Persons with Hemophilia A Treated with Emicizumab: A Survey Study of Hematologists in the US

Wendy E. Owens, MA, Anisha M. Patel, PhD, Kathleen Poulos, RN, Janet Bernard, BA, Janet Powers, MPH, MBA, Richard H. Ko, MD

Blood (2019) 134 (Supplement_1): 4941.

https://doi.org/10.1182/blood-2019-123730

Published: 2019

Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Michael Callaghan, MD, Benjamin Trzaskoma, MS, Richard H. Ko, MD, Lucy Lee, PharmD, Anisha M. Patel, PhD, Eunice Tzeng, PharmD, Michelle Lynn Shah, PharmD, Tiffany Y. Chang, MD MAS, Markus Niggli, PhD, Christophe Dhalluin, PhD, Johnny Mahlangu, MMed, FCPath

Blood (2019) 134 (Supplement_1): 2395.

https://doi.org/10.1182/blood-2019-123654

Published: 2019

Journal Articles

Estimating the Burden of Intracranial Hemorrhage in Persons with Hemophilia A using Administrative Claims Data

Arash Mahajerin, MD MS, Anisha M. Patel, PhD, Erru Yang, MS, Chinelo C. Orji, MS, Richard H. Ko, MD

Blood (2019) 134 (Supplement_1): 2398.

https://doi.org/10.1182/blood-2019-123713

Published: 2019

Journal Articles

Understanding Disease Burden Among Persons with Hemophilia Α without Inhibitors

Wendy E Owens, MA, Anissa Cyhaniuk, Anisha Patel, Karina Raimundo, Elaine Chan, Richard H Ko

Blood (2018) 132 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2018-99-112121

Published: 2018

Journal Articles

Management of Persons with Hemophilia A with Inhibitors After Emicizumab Approval

Anisha Patel, Karina Raimundo, Corey Stepule, Jennifer Whiteley, Richard H Ko

Blood (2018) 132 (Supplement 1): 5020.

https://doi.org/10.1182/blood-2018-99-116176

Published: 2018

Journal Articles

Pain Management in Hemophilia Α: Analysis of a Large US Insurance Claims Database

Mahek Garg, Karina Raimundo, Anisha Patel, Richard H Ko

Blood (2018) 132 (Supplement 1): 2234.

https://doi.org/10.1182/blood-2018-99-116989

Published: 2018

Journal Articles

Development of a Concept-Driven Disease Impact Instrument from Patients with Hemophilia (Pediatric and Adult) and Caregivers

Jessica T. Markowitz, Esprit Ma, Paul Solari, Patrick Marquis, Amy D. Shapiro, MD, Barbara Konkle, MD, Peter Trask, Edmund Pezalla, Anna Christian, Michelle Rice, Wendy E. Owens, MA, Kimberly Haugstad, Yaping Xu, Richard H. Ko, Jennifer Whiteley, Robert F. Sidonio

Blood (2017) 130 (Supplement 1): 4732.

https://doi.org/10.1182/blood.V130.Suppl_1.4732.4732

Published: 2017

Journal Articles

Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)

Rebecca Kruse-Jarres, Michael U. Callaghan, Stacy E. Croteau, MD, Victor Jimenez-Yuste, Liane Khoo, Ri Liesner, Tadashi Matsushita, Michael Recht, Guy Young, Tiffany Chang, Christophe Dhalluin, Yunming Mu, Jin Xu, Jenny Devenport, Richard H. Ko, Paul Solari, Johannes Oldenburg

Blood (2017) 130 (Supplement 1): 89.

https://doi.org/10.1182/blood.V130.Suppl_1.89.89

Published: 2017

Journal Articles

Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete Remission (CR) Rates): A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Richard H. Ko, MD, Lingyun Ji, MS, Richard Sposto, PhD, Phillip Barnette, MD, Bruce Bostrom, MD, Raymond Hutchinson, MD, Elizabeth Raetz, MD, Nita Seibel, MD, Clare Twist, MD, Elena Eckroth, BA, Paul Gaynon, MD, Mignon Loh, MD

Blood (2007) 110 (11): 854.

https://doi.org/10.1182/blood.V110.11.854.854

Published: 2007

NARROW

BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton's Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia

Cost-Effectiveness of Emicizumab Vs Efanesoctocog Alfa, Standard Half Life (SHL) and Other Extended Half Life (EHL) FVIII Products for Prophylaxis in People with Severe Hemophilia a without Inhibitors

Cost-Effectiveness of Emicizumab for Prophylaxis in People with Severe Hemophilia A without Inhibitors

Characterizing Mild and Moderate Hemophilia A Patients in the Real World: A Patient-Centric Approach

Evaluation of the Safety of Emicizumab Prophylaxis in Persons with Hemophilia A: An Updated Summary of Thrombotic Events and Thrombotic Microangiopathies

Improvement in Annualized Bleed Rate in Patients with Hemophilia A Initiating Emicizumab - Physician Reported Outcomes from the Adelphi Hemophilia a Disease Specific Programme™

A Novel Methodology for Building Longitudinal, Patient-Centric Real World Datasets in Hemophilia A

A Phase IV, Multicenter, Open-Label Study of Emicizumab Prophylaxis in Persons with Hemophilia a with or without FVIII Inhibitors Undergoing Minor Surgical Procedures

Characterization and Disease Management of Persons with Hemophilia A Treated with Emicizumab: A Survey Study of Hematologists in the US

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Estimating the Burden of Intracranial Hemorrhage in Persons with Hemophilia A using Administrative Claims Data

Understanding Disease Burden Among Persons with Hemophilia Α without Inhibitors

Management of Persons with Hemophilia A with Inhibitors After Emicizumab Approval

Pain Management in Hemophilia Α: Analysis of a Large US Insurance Claims Database

Development of a Concept-Driven Disease Impact Instrument from Patients with Hemophilia (Pediatric and Adult) and Caregivers

Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)

Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete Remission (CR) Rates): A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only